Trial Profile
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Cetuximab
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Sep 2023 Number of treatment arms have been increased from 2 to 3 by the addition of Experimental: (Lead-in) RT + Durvalumab arm. Timelines for primary end points have been increased.
- 27 Sep 2023 Planned End Date changed from 28 Jun 2024 to 21 Sep 2024.
- 30 Jun 2023 Planned End Date changed from 31 Dec 2025 to 28 Jun 2024.